Patient characteristics at RESPITE baseline (the last documented value while still receiving phosphodiesterase-5 inhibitor)
| Characteristic | Riociguat up to 2.5 mg t.i.d. (n=61) |
| Female | 45 (74) |
| Caucasian | 56 (92) |
| BMI kg·m−2 | 28±5 |
| Dana Point classification of PH | |
| 1.1 Idiopathic PAH | 56 (92) |
| 1.2 Heritable PAH | 1 (2) |
| 1.3 Drug- or toxin-induced PAH | 1 (2) |
| 1.4 PAH associated with congenital heart disease | 2 (3) |
| 1.4 PAH associated with connective tissue disease# | 1 (2) |
| Concomitant treatment with ERA | 50 (82) |
| Pretreated with sildenafil | 40 (66) |
| Pretreated with tadalafil | 21 (34) |
| Concomitant diuretic use | 45 (74) |
| Time since first PH diagnosis years | 4±4 |
| 6MWD m | 357±81 |
| WHO FC III | 61 (100) |
| NT-proBNP¶ pg·mL−1 | 1190±1828 |
| eGFR mL·min−1·1.73 m−2 | 73±22 |
| PVR dyn·s·cm–5 | 835±272 |
| Cardiac output L·min−1 | 4.2±0.8 |
| Cardiac index L·min−1·m−2 | 2.3±0.4 |
| mPAP mmHg | 52±12 |
| RAP mmHg | 8.3±4.9 |
| SvO2¶ % | 64.8±6.9 |
| SVR+ dyn·s·cm–5 | 1624±452 |
| PAWP mmHg | 9.4±3.2 |
| SBP mmHg | 118±15 |
| DBP mmHg | 72±9 |
| Heart rate beats per min | 75±11 |
Data are presented as n (%) or mean±sd, unless otherwise stated. #: protocol violation; patient randomised due to investigator error; ¶: n=58; +: n=60. BMI: body mass index; PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; ERA: endothelin receptor antagonist; 6MWD: 6-min walking distance; WHO FC: World Health Organization functional class; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; eGFR: estimated glomerular filtration rate; PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; RAP: right atrial pressure; SvO2: mixed venous oxygen saturation; SVR: systemic vascular resistance; PAWP: pulmonary artery wedge pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.